The role of steroids in severe CAP

References

• Chalmers JD. Corticosteroids for community-acquired pneumonia: a critical view of the evidence. Eur Respir J. 2016;48:984–986.
   PubMedGoogle Scholar
• Shindo Y, Ito R, Kobayashi D, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis. 2015;15:1055–1065.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13:3–10.
   PubMed Web of Science ®Google Scholar
• Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. J Am Med Assoc. 2019;321:2003–2017.
   PubMed Web of Science ®Google Scholar
• Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776–787.
   PubMed Web of Science ®Google Scholar
• Pereira JM, Lisboa T, Paiva JA. Adjuvant therapies in critical care: steroids to treat infectious diseases. Intensive Care Med. 2018;44:1306–1309.
   PubMed Web of Science ®Google Scholar
• Torres A, Ferrer M, Niederman MS. Adjuvant therapies in critical care: steroids in community-acquired pneumonia. Intensive Care Med. 2018;44:478–481.
   PubMed Web of Science ®Google Scholar
• Blasi F, Aliberti S, Pappalettera M, et al. 100 years of respiratory medicine: pneumonia. Respir Med. 2007;101:875–881.
   PubMed Web of Science ®Google Scholar
• Fass RJ. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother. 1993;32(Suppl):A:17–27.
   PubMedGoogle Scholar
• Donowitz GR. Community-acquired pneumonia: 2012 history, mythology, and science. Trans Am Clin Climatol Assoc. 2013;124:283–293.
   PubMedGoogle Scholar
• Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080–2084.
   PubMed Web of Science ®Google Scholar
• Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637.
   PubMedGoogle Scholar
• Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017 Dec 13;(12):CD007720.
   PubMed Web of Science ®Google Scholar
• Meijvis SCA, van de Garde EMW, Rijkers GT, et al. Treatment with anti-inflammatory drugs in community-acquired pneumonia. J Intern Med. 2012;272:25–35.
   PubMed Web of Science ®Google Scholar
• Niederman MS. Recent advances in community-acquired pneumonia. Chest. 2007;131:1205–1215.
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133:610–617.
   PubMed Web of Science ®Google Scholar
• Morgan AJ, Glossop AJ. Severe community-acquired pneumonia. BJA Educ. 2016;16:167–172.
   Web of Science ®Google Scholar
• Prina E, Ceccato A, Torres A. New aspects in the management of pneumonia. Crit Care. 2016;20:1–9.
   PubMed Web of Science ®Google Scholar
• Loeches IM, Torres A, Povoa P, et al. The association of cardiovascular failure with treatment for ventilator ‑ associated lower respiratory tract infection. Intensive Care Med. 2019. DOI:10.1007/s00134-019-05797-6.
   Web of Science ®Google Scholar
• Salluh JIF, Soares M, Singer M. Spreading the knowledge on the epidemiology of sepsis. Lancet Infect Dis. 2017;17:1104–1106.
   PubMed Web of Science ®Google Scholar
• Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169:910–914.
   PubMed Web of Science ®Google Scholar
• Sibila O, Ferrer M, Agustí C. Torres a. Corticosteroids as adjunctive treatment in community-acquired pneumonia. Minerva Anestesiol. 2014;80:1336–1344.
   PubMed Web of Science ®Google Scholar
• Rañó A, Agustí C, Sibila O, et al. Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. Curr Opin Infect Dis. 2006;19:179–184.
   PubMed Web of Science ®Google Scholar
• Rabello L, Pitrowsky MT, Sores M, et al. Novel biomarkers in severe community-acquired pneumonia. Rev Bras Ter Intensiva. 2011;23:499–506.
   PubMedGoogle Scholar
• de Pascale G, Bello G, Antonelli M. Steroids in severe pneumonia: a literature review. Minerva Anestesiol. 2011;77:902–910.
   PubMed Web of Science ®Google Scholar
• Martínez R, Menéndez R, Reyes S, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J. 2011;37:393–399.
   PubMed Web of Science ®Google Scholar
• Martin C, Saux P, Mege JL, et al. Prognostic values of serum cytokines in septic shock. Intensive Care Med. 1994;20:272–277.
   PubMed Web of Science ®Google Scholar
• Puren AJ, Feldman C, Savage N, et al. Patterns of cytokine expression in community-acquired pneumonia. Chest. 1995;107:1342–1349.
   PubMed Web of Science ®Google Scholar
• Montón C, Torres A, El-Ebiary M, et al. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med. 1999;27:1745–1753.
   PubMed Web of Science ®Google Scholar
• Fernández-Serrano S, Dorca J, Coromines M, et al. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 2003;10:813–820.
   PubMedGoogle Scholar
• Ioanas M, Ferrer M, Cavalcanti M, et al. Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. Crit Care Med. 2004;32:938–945.
   PubMed Web of Science ®Google Scholar
• Rae N, Finch S, Chalmers JD. Cardiovascular disease as a complication of community-acquired pneumonia. Curr Opin Pulm Med. 2016;22:212–218.
   PubMed Web of Science ®Google Scholar
• Endeman H, Meijvis SCA, Rijkers GT, et al. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J. 2011;37:1431–1438.
   PubMed Web of Science ®Google Scholar
• Wunderink RG. Corticosteroids for severe community-acquired pneumonia: not for everyone. J Am Med Assoc. 2015;313:673–674.
   Web of Science ®Google Scholar
• Torres A. Corticosteroids for severe CAP: the pros. Rev Bras Ter Intensiva. 2015;27:202–204.
   PubMedGoogle Scholar
• Lisboa T, Salluh JIF, Friedman G. Macrolides and respiratory infection in critically ill patients: what is the next step? Minerva Anestesiol. 2016;82:221–229.
   PubMed Web of Science ®Google Scholar
• Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44:438–448.
   PubMed Web of Science ®Google Scholar
• Khan AR, Riaz M, Bin Abdulhak AA, et al. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2013;8:e52929.
   PubMed Web of Science ®Google Scholar
• Karakioulaki M, Stolz D. Biomarkers in pneumonia-beyond procalcitonin. Int J Mol Sci. 2019;20:1–18.
   Web of Science ®Google Scholar
• Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. J Am Med Assoc. 2015;313:677–686.
   PubMed Web of Science ®Google Scholar
• Perren A, Cerutti B, Lepori M, et al. Influence of steroids on Procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection. 2008;36:163–166.
   PubMed Web of Science ®Google Scholar
• Salluh JI, Soares M, Coelho LM, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care. 2011;26:193–200. S0883-9441(10)00192-9.
   PubMed Web of Science ®Google Scholar
• Sibila O, Agustí C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J. 2008;32:259–264.
   PubMed Web of Science ®Google Scholar
• Haegeman G. Inhibition of signal transduction pathways involved in inflammation. Eur Respir J Suppl . 2003;22:16–19.
   Google Scholar
• Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology. 1940;27:367–374.
   Google Scholar
• Marik PE. Critical illness-related corticosteroid insufficiency. Chest J. 2009;135:181.
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242–248.
   PubMed Web of Science ®Google Scholar
• Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15. DOI:10.1186/cc10103.
   Google Scholar
• Nafae RM, Ragab MI, Amany FM, et al. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc. 2013;62:439–445.
   Google Scholar
• Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511–1518.
   PubMed Web of Science ®Google Scholar
• Meijvis SCA, Hardeman H, Remmelts HHF, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:2023–2030.
   PubMed Web of Science ®Google Scholar
• Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512–520.
   PubMed Web of Science ®Google Scholar
• Agustí C, Rañó A, Filella X, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003;123:488–498.
   PubMed Web of Science ®Google Scholar
• Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218–220.
   PubMed Web of Science ®Google Scholar
• Sibila O, Luna CM, Agustí C, et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J. 2008;32:1037–1046.
   PubMed Web of Science ®Google Scholar
• Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–871.
   PubMed Web of Science ®Google Scholar
• Salluh JIF, Póvoa P, Soares M, et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care. 2008;12:1–7.
   Web of Science ®Google Scholar
• Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J. 2007;30:951–956.
   PubMed Web of Science ®Google Scholar
• Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest. 1993;104:389–392.
   PubMed Web of Science ®Google Scholar
• Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185:249–255.
   PubMed Web of Science ®Google Scholar
• Schünemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006;174:605–614.
   PubMed Web of Science ®Google Scholar
• Snijders D, Daniels JMA, De Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975–982.
   PubMed Web of Science ®Google Scholar
• Sabry NA, Omar EE-D. Corticosteroids and ICU course of community acquired pneumonia in egyptian settings. Pharmacol Pharm. 2011;02:73–81.
   Google Scholar
• Wirz SA, Blum CA, Schuetz P, et al. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. Eur Respir J. 2016;48:1150–1159.
   PubMed Web of Science ®Google Scholar
• Chon GR, Lim C-M, Koh Y, et al. Analysis of systemic corticosteroid usage and survival in patients requiring mechanical ventilation for severe community-acquired pneumonia. J Infect Chemother. 2011;17:449–455.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Horiguchi H, et al. Low-dose corticosteroids use and mortality in severe community-acquired pneumonia patients. Eur Respir J. 2015;45:463–472.
   PubMed Web of Science ®Google Scholar
• Siempos II, Vardakas KZ, Kopterides P, et al. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008;62:661–668.
   PubMed Web of Science ®Google Scholar
• Nie W, Zhang Y, Cheng J, et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 2012;7:1–7.
   Web of Science ®Google Scholar
• Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis. 2018;66:346–354.
   PubMed Web of Science ®Google Scholar
• Fang F, Zhang Y, Tang J, et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern Med. 2019;179:213–223.
   PubMed Web of Science ®Google Scholar
• Huang J, Guo J, Li H, et al. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14636.
   PubMed Web of Science ®Google Scholar
• Cheng M, Pan Z-Y, Yang J, et al. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care. 2014;59:557–563.
   PubMedGoogle Scholar
• Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:519–528.
   PubMed Web of Science ®Google Scholar
• Horita N, Otsuka T, Haranaga S, et al. Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep. 2015;5:1–8.
   Web of Science ®Google Scholar
• Chen L, Chen J, Chen Y, et al. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. World J Emerg Med. 2015;6:172–178.
   PubMed Web of Science ®Google Scholar
• Wan Y-D, Sun T-W, Liu Z-Q, et al. Efficacy and safety of corticosteroids for community-acquired pneumonia. Chest. 2016;149:209–219.
   PubMed Web of Science ®Google Scholar
• Bi J, Yang J, Wang Y, et al. Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis. PLoS One. 2016;11:1–15.
   Web of Science ®Google Scholar
• Wu WF, Fang Q, He GJ. Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. Am J Emerg Med. 2018;36:179–184.
   PubMed Web of Science ®Google Scholar
• Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386:1097–1108.
   PubMed Web of Science ®Google Scholar
• Marti C, Grosgurin O, Harbarth S, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2015;10:1–15.
   Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - Full version. Clin Microbiol Infect. 2011;17:E1–59.
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society And Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–67.
   PubMed Web of Science ®Google Scholar
• Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California expert panel for corticosteroids as adjunctive therapy. N Engl J Med. 1990;323:1500–1504.
   PubMed Web of Science ®Google Scholar
• Briel M, Boscacci R, Furrer H, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis. 2005;5:1–8.
   PubMed Web of Science ®Google Scholar
• Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;4:CD006150.
   Google Scholar
• Wang L, Liang H, Ye L, et al. Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: a meta-analysis. Exp Ther Med. 2016;11:683–687.
   PubMed Web of Science ®Google Scholar
• Newberry L, O’Hare B, Kennedy N, et al. Early use of corticosteroids in infants with a clinical diagnosis of Pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial. Paediatr Int Child Health. 2017;37:121–128.
   PubMed Web of Science ®Google Scholar
• Wieruszewski PM, Barreto JN, Frazee E, et al. Early corticosteroids for pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest. 2018;154:636–644.
   PubMed Web of Science ®Google Scholar
• Lemiale V, Debrumetz A, Delannoy A, et al. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res. 2013;14:1–7.
   PubMed Web of Science ®Google Scholar
• Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest. 1998;114:426–431.
   PubMed Web of Science ®Google Scholar
• Cheng VCC, Tang BSF, Wu AKL, et al. Medical treatment of viral pneumonia including SARS in immunocompetent adult. J Infect. 2004;49:262–273.
   PubMed Web of Science ®Google Scholar
• Corrigan R, Carter R, Raza M. Use of steroids for management of varicella pneumonia. BMJ Case Rep. 2015. DOI:10.1136/bcr-2015-210866
   PubMedGoogle Scholar
• Ahmed R, Ahmed QAA, Adhami NA, et al. Varicella pneumonia: another “steroid responsive” pneumonia? J Chemother. 2002;14. DOI:10.1179/joc.2002.14.2.220
   Web of Science ®Google Scholar
• Sené T, Gallien S, Delaugerre C, et al. Varicella pneumonia in an immunocompetent adult. Respiration. 2013;86:66.
   PubMed Web of Science ®Google Scholar
• Adhami N, Arabi Y, Raees A, et al. Effect of corticosteroids on adult varicella pneumonia: cohort study and literature review. Respirology. 2006;11:437–441.
   PubMed Web of Science ®Google Scholar
• Goldman M, Johnson PC, Sarosi GA. Fungal pneumonias: the endemic mycoses. Clin Chest Med. 1999;20:507–519.
   PubMed Web of Science ®Google Scholar
• Lahm T, Neese S, Thomburg AT, et al. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest. 2008;133:1478–1480.
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–825.
   PubMed Web of Science ®Google Scholar
• Nedel WL, Nora D, Salluh JIF, et al. Corticosteroids for severe influenza pneumonia: a critical appraisal. World J Crit Care Med. 2016;5:89.
   PubMedGoogle Scholar
• Moreno G, Rodríguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 2018;44:1470–1482.
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Richard JCM, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183:1200–1206.
   PubMed Web of Science ®Google Scholar
• Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011;183:1207–1214.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2011;37:272–283.
   PubMed Web of Science ®Google Scholar
• Cavallazzi R, Ramirez JA. Using steroids in patients with community-acquired pneumonia at the University of Louisville Hospital: who, what, and when. Univ Louisv J Respir Infect. 2017;1:4–6.
   Google Scholar
• Waterer G, Metersky ML. Corticosteroids for community-acquired pneumonia: overstated benefits and understated risks. Chest. 2019;1–5. DOI:10.1016/j.chest.2019.06.017
   Web of Science ®Google Scholar
• Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. N Engl J Med. 2013;368:1477–1488.
   PubMed Web of Science ®Google Scholar
• Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195–203.
   PubMed Web of Science ®Google Scholar
• Rubin R. Wide interest in a vitamin C drug cocktail for sepsis despite lagging evidence. J Am Med Assoc. 2019;322:291–293.
   Web of Science ®Google Scholar
• Brant EB, Angus DC. Is high-dose vitamin C beneficial for patients with sepsis? JAMA. 2019;322:1257–1258.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2017;23:234–241.
   PubMed Web of Science ®Google Scholar
• Roquilly A, Mahe PJ, Guitton C, et al. Hydrocortisone therapy for patients with multiple trauma. JAMA. 2011;305:1201–1209.
   PubMed Web of Science ®Google Scholar
• Asehnoune K, Seguin P, Allary J, et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir Med. 2014;2:706–716.
   PubMed Web of Science ®Google Scholar
• Salluh JIF, Póvoa P. Hydrocortisone and treatment of multiple trauma - letter. JAMA. 2011;306:41–42.
   PubMedGoogle Scholar
• Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378:809–818.
   PubMed Web of Science ®Google Scholar
• Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378:797–808. NEJMoa1705835.
   Web of Science ®Google Scholar
• Fred HL. The SASH phenomenon: calling attention to the natural history of diseases. Texas Hear Inst J. 2019;46:92.
   PubMed Web of Science ®Google Scholar
• Annane D. Corticosteroids and pneumonia: time to change practice. Lancet. 2015;385:1484–1485.
   PubMed Web of Science ®Google Scholar
• Baskar V, Sum CF, Lim SC. Prednisone for community-acquired pneumonia: not yet time. Lancet. 2015;386:431.
   PubMed Web of Science ®Google Scholar